Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 3/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.40 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP1 | P63208 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4418327 | 0.92 | USP30 (0.40) | USP30EGFRSRCHDAC6SMARCA2 | |
| SCHEMBL4415912 | 0.90 | USP30 (0.41) | USP30EGFRSRCBACE1ABCB1 | |
| SCHEMBL4410015 | 0.90 | SCN9A (0.42) | USP30BACE1HDAC6SMARCA2SMARCA4 | |
| SCHEMBL4413014 | 0.89 | GPR119 (0.40) | USP30EGFRSRCBACE1ABCB1 | |
| SCHEMBL4408213 | 0.87 | USP30 (0.43) | USP30EGFRSRCABCB1HDAC6 | |
| SCHEMBL4412319 | 0.85 | USP30 (0.43) | USP30 | |
| SCHEMBL4408961 | 0.85 | USP30 (0.43) | USP30ABCB1HDAC6UCHL1SMARCA2 | |
| SCHEMBL4410012 | 0.85 | USP30 (0.42) | USP30BACE1 | |
| SCHEMBL4415998 | 0.84 | USP30 (0.42) | USP30HDAC6HDAC8ACKR3 | |
| SCHEMBL4410166 | 0.84 | USP30 (0.51) | USP30EGFRSRCBACE1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | HTR2C, HTR2A, HTR5A | USP30 4369/4885EGFR 1635/4885SRC 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.